Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma

Oral Oncology

Volumn 57, Issue , 2016, Pages 54-60

  Kondo, Yuta ^a   Ohno, Tatsukuni ^a   Nishii, Naoto ^a   Harada, Kiyoshi ^a   Yagita, Hideo ^b   Azuma, Miyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CTLA 4; Head and neck squamous cell carcinoma; Immune checkpoint inhibitor; Immunotherapy; PD 1; Tumor microenvironment; VISTA

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNE CHECKPOINT INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MIH63; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; UNCLASSIFIED DRUG; V DOMAIN CONTAINING IG SUPPRESSOR OF T CELL ACTIVATION; B7 ANTIGEN; CTLA4 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; VISTA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE MIGRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; SQUAMOUS CELL CARCINOMA;

B7 ANTIGENS; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84968867052     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2016.04.005     Document Type: Article

References (36)

1. V. Shankaran, H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, and et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 2001 1107 1111
2. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance Immunol Rev 182 2001 18 32
3. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 8 2008 467 477
4. S. Ostrand-Rosenberg Tolerance and immune suppression in the tumor microenvironment Cell Immunol 299 2016 23 29
5. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
6. P.A. Ott, F.S. Hodi, and C. Robert CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients Clin Cancer Res: Off J Am Assoc Cancer Res 19 2013 5300 5309
7. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, A.M. Lesokhin, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
8. C. Kyi, and M.A. Postow Checkpoint blocking antibodies in cancer immunotherapy FEBS Lett 588 2014 368 376
9. N. Gildener-Leapman, R.L. Ferris, and J.E. Bauman Promising systemic immunotherapies in head and neck squamous cell carcinoma Oral Oncol 49 2013 1089 1096
10. M.S. Swanson, and U.K. Sinha Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data Oral Oncol 51 2015 12 15
11. L. Wang, R. Rubinstein, J.L. Lines, A. Wasiuk, C. Ahonen, Y. Guo, and et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses J Exp Med 208 2011 577 592
12. D.B. Flies, S. Wang, H. Xu, and L. Chen Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models J Immunol 187 2011 1537 1541
13. L. Wang, I. Le Mercier, J. Putra, W. Chen, J. Liu, A.D. Schenk, and et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity Proc Natl Acad Sci USA 111 2014 14846 14851
14. D.B. Flies, X. Han, T. Higuchi, L. Zheng, J. Sun, J.J. Ye, and et al. Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity J Clin Invest 124 2014 1966 1975
15. D.B. Flies, T. Higuchi, and L. Chen Mechanistic assessment of PD-1H coinhibitory receptor-induced T cell tolerance to allogeneic antigens J Immunol 194 2015 5294 5304
16. I. Le Mercier, W. Chen, J.L. Lines, M. Day, J. Li, P. Sergent, and et al. VISTA regulates the development of protective antitumor immunity Cancer Res 74 2014 1933 1944
17. J. Liu, Y. Yuan, W. Chen, J. Putra, A.A. Suriawinata, A.D. Schenk, and et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses Proc Natl Acad Sci USA 112 2015 6682 6687
18. D. Khurana, E.A. Martin, J.L. Kasperbauer, B.W. O'Malley Jr., D.R. Salomao, L. Chen, and et al. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy Head Neck 23 2001 899 906
19. B.W. O'Malley, K.A. Cope, S.H. Chen, D. Li, M.R. Schwarta, and S.L. Woo Combination gene therapy for oral cancer in a murine model Cancer Res 56 1996 1737 1741
20. J. Piao, Y. Kamimura, H. Iwai, Y. Cao, K. Kikuchi, M. Hashiguchi, and et al. Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours Immunology 127 2009 489 499
21. S. Mogi, J. Sakurai, T. Kohsaka, S. Enomoto, H. Yagita, K. Okumura, and et al. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells Immunology 101 2000 541 547
22. T. Yamazaki, H. Akiba, A. Koyanagi, M. Azuma, H. Yagita, and K. Okumura Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-γ-induced nitric oxide production J Immunol 175 2005 1586 1592
23. T. Oikawa, Y. Kamimura, H. Akiba, H. Yagita, K. Okumura, H. Takahashi, and et al. Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease J Immunol 177 2006 4281 4287
24. N. Chalermsarp, and M. Azuma Identification of three distinct subsets of migrating dendritic cells from oral mucosa within the regional lymph nodes Immunology 127 2009 558 566
25. H. Kobori, M. Hashiguchi, J. Piao, M. Kato, P. Ritprajak, and M. Azuma Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites Immunology 130 2010 363 373
26. A.M. Paterson, S.B. Lovitch, P.T. Sage, V.R. Juneja, Y. Lee, J.D. Trombley, and et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity J Exp Med 2015
27. + T cells J Exp Med 212 2015 1125 1137
28. C.T. Victor, A.J. Rech, A. Maity, R. Rengan, K.E. Pauken, E. Stelekati, and et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 2015
29. + T cells Cancer Immunol Res 3 2015 116 124
30. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci USA 107 2010 4275 4280
31. J. Duraiswamy, K.M. Kaluza, G.J. Freeman, and G. Coukos Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors Cancer Res 73 2013 3591 3603
32. R. Das, R. Verma, M. Sznol, C.S. Boddupalli, S.N. Gettinger, H. Kluger, and et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo J Immunol 194 2015 950 959
33. H.B. Jie, N. Gildener-Leapman, J. Li, R.M. Srivastava, S.P. Gibson, T.L. Whiteside, and et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients Br J Cancer 109 2013 2629 2635
34. + regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis Cancer Res 75 2015 2200 2210
35. C. Twyman-Saint Victor, A.J. Rech, A. Maity, R. Rengan, K.E. Pauken, E. Stelekati, and et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 2015 373 377
36. K.S. Peggs, S.A. Quezada, C.A. Chambers, A.J. Korman, and J.P. Allison Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies J Exp Med 206 2009 1717 1725